Evidence map›Paper›PMID 30740824›Full record

ArticleHuman mutation2019

A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes.

Richard Gallon, Barbara Mühlegger, Sören-Sebastian Wenzel, Harsh Sheth, Christine Hayes, Stefan Aretz, Karin Dahan, William Foulkes, Christian P Kratz, Tim Ripperger and 25 more

Open access · hybridAbstract read
In one paragraph

Article in Human mutation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Genotype-phenotype correlations inOncology reviews · 2025
    Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Assessment of Microsatellite Instability from Next-Generation Sequencing Data.Advances in experimental medicine and biology · 2022
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 12 countries.

Richard GallonInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.ORCID 0000-0002-5395-0099
Barbara MühleggerDivision of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Sören-Sebastian WenzelDivision of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Harsh ShethInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Christine HayesInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Stefan AretzInstitute of Human Genetics, Biomedical Centre, University Hospital Bonn, Bonn, Germany.
Karin DahanCentre de génétique humaine, Institut de pathologie et génétique (IPG), Gosselies, Belgium.
William FoulkesProgram in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada.ORCID 0000-0001-7427-4651
Christian P KratzDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Tim RippergerDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Amedeo A AziziDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Hagit Baris FeldmanThe Genetics Institute, Rambam Health Care Campus, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Anne-Laure ChongDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada.
Ugur DemirsoyDepartment of Pediatric Oncology, Kocaeli University, Kocaeli, Turkey.
Benoît FlorkinDepartment of Pediatrics, CHR Citadelle Hospital, University of Liège, Liège, Belgium.
Thomas ImschweilerPediatric Oncology, Helios-Klinikum, Krefeld, Germany.
Danuta Januszkiewicz-LewandowskaDepartment of Pediatric Oncology, Hematology and Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Stephan LobitzDepartment of Pediatric Oncology/Pediatric Hematology, Kliniken der Stadt Köln gGmbH, Children's Hospital Amsterdamer Strasse, Köln, Germany.
Michaela NathrathPediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany.
Hans-Jürgen PanderInstitut für Klinische Genetik, Olgahospital, Stuttgart, Germany.
Vanesa Perez-AlonsoPediatrics Department, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
Claudia PerneInstitute of Human Genetics, Biomedical Centre, University Hospital Bonn, Bonn, Germany.
Iman RagabPediatrics Department, Hematology-Oncology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Thorsten RosenbaumDepartment of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany.
Daniel RuedaHereditary Cancer Laboratory, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
Markus G SeidelResearch Unit Pediatric Hematology and Immunology, Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.
Manon SuerinkDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands.
Julia TaeubnerDepartment of Pediatric Oncology, Hematology and Clinical Immunology, University Children´s Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.
Stefanie-Yvonne ZimmermannDepartment of Pediatric Hematology and Oncology, Children's Hospital, University Hospital, Frankfurt, Germany.
Johannes ZschockeDivision of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
Gillian M BorthwickInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
John BurnInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Michael S JacksonInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Mauro Santibanez-KorefInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom.
Katharina WimmerDivision of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-0732-7538
Newcastle University · GBInnsbruck Medical University · ATMcGill University Health Centre · CAMedizinische Hochschule Hannover · DEResearch Institute Hospital 12 de Octubre · ESUniversity Hospital Bonn · DEAin Shams University · EGGoethe University Frankfurt · DEHeinrich Heine University Düsseldorf · DEHelios Klinikum Krefeld · DEInstitute of Pathology and Genetics · BEKliniken der Stadt Köln · DEKlinikum Kassel · DEKocaeli Üniversitesi · TRLeiden University Medical Center · NLMedical University of Graz · ATMedical University of Vienna · ATOlgahospital · DEPoznan University of Medical Sciences · PLSana Kliniken Duisburg · DE

Funding

Cancer Research UK 15934Cancer Research UK C569/A24991
6 · The paper itself

Abstract

Constitutional mismatch repair deficiency (CMMRD) is caused by germline pathogenic variants in both alleles of a mismatch repair gene. Patients have an exceptionally high risk of numerous pediatric malignancies and benefit from surveillance and adjusted treatment. The diversity of its manifestation, and ambiguous genotyping results, particularly from PMS2, can complicate diagnosis and preclude timely patient management. Assessment of low-level microsatellite instability in nonneoplastic tissues can detect CMMRD, but current techniques are laborious or of limited sensitivity. Here, we present a simple, scalable CMMRD diagnostic assay. It uses sequencing and molecular barcodes to detect low-frequency microsatellite variants in peripheral blood leukocytes and classifies samples using variant frequencies. We tested 30 samples from 26 genetically-confirmed CMMRD patients, and samples from 94 controls and 40 Lynch syndrome patients. All samples were correctly classified, except one from a CMMRD patient recovering from aplasia. However, additional samples from this same patient tested positive for CMMRD. The assay also confirmed CMMRD in six suspected patients. The assay is suitable for both rapid CMMRD diagnosis within clinical decision windows and scalable screening of at-risk populations. Its deployment will improve patient care, and better define the prevalence and phenotype of this likely underreported cancer syndrome.

Indexed as

DNA Mismatch RepairGenetic Association StudiesGenetic Predisposition to DiseaseMicrosatellite InstabilityAllelesBrain NeoplasmsColorectal NeoplasmsGerm-Line MutationHumansLeukocytesMicrosatellite RepeatsNeoplastic Syndromes, HereditaryConstitutional mismatch repair deficiencygenetic diagnosticsmicrosatellite instabilitynext-generation sequencingsingle molecule molecular inversion probesvariant classification

Identifiers

PMID30740824
PMCPMC6519362
OpenAlexW2911493108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.